SCHEMBL243515

SCHEMBL243515

Nc1nc(Cl)nc2c1ncn2C1CCCCO1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.69
TP53 P04637 2/20 0.61
CYP2C9 P11712 1/20 0.61
NFKB1 P19838 1/20 0.61
MAPK1 P28482 1/20 0.61
HSD17B10 Q99714 1/20 0.61
MEN1 O00255 1/20 0.61
ALDH1A1 P00352 1/20 0.61
APEX1 P27695 1/20 0.61
PI4KA P42356 1/20 0.61
BLM P54132 1/20 0.61
KMT2A Q03164 1/20 0.61
ADCY1 Q08828 1/20 0.61
PI4K2B Q8TCG2 1/20 0.61
PI4K2A Q9BTU6 1/20 0.61
PI4KB Q9UBF8 1/20 0.61
PDE4D Q08499 2/20 0.54
PDE3A Q14432 2/20 0.54
PNP P00491 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29354479 1.00 YTHDC1 (0.69) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL20275396 1.00 YTHDC1 (0.69) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL4148488 0.96 TP53 (0.66) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL2489808 0.95 YTHDC1 (0.64) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL20275400 0.87 YTHDC1 (0.72) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL244963 0.87 YTHDC1 (0.72) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL29353722 0.87 YTHDC1 (0.72) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL17262848 0.87 PI4KA (0.64) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL1713275 0.86 YTHDC1 (0.79) YTHDC1TP53CYP2C9NFKB1MAPK1
SCHEMBL9885109 0.86 YTHDC1 (0.74) YTHDC1TP53CYP2C9NFKB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4241063-A Purine derivatives and their use as bronchodilators BRISTOL-MYERS COMPANY (US) 1980-12-23 US claimed
JP-57163382-A None JP disclosed
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates AMBRX, INC. (US) 2026-03-10 US disclosed
EP-4562011-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF Zymeworks BC Inc. (CA) 2025-06-04 EP disclosed
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2025-05-29 US disclosed
WO-2024199063-A1 PHOSPHORUS OR SULFUR-CONTAINING MACROCYCLE AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 WO disclosed
WO-2024199069-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 WO disclosed
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed
WO-2024020684-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2024-02-01 WO disclosed
CN-117263939-A Adenine derivative, preparation method and application thereof, and immune adjuvant system 成都迈科康生物科技有限公司 2023-12-22 CN disclosed
US-20070190071-A1 9-Substituted 8-oxoadenine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 US disclosed
US-20070190071-A1 9-Substituted 8-oxoadenine compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 US disclosed
WO-2007034173-A1 PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS ASTRAZENECA AB (SE) 2007-03-29 WO disclosed
WO-2007031726-A1 PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES ASTRAZENECA AB (SE) 2007-03-22 WO disclosed
EP-1734968-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES Novartis AG (CH) 2006-12-27 EP disclosed
EP-1728793-A1 9-SUBSTITUTED 8-OXOADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 EP disclosed
EP-1728792-A1 8-OXOADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 EP disclosed
WO-2005097135-A2 USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES NOVARTIS AG (CH) 2005-10-20 WO disclosed
JP-S57163382-A PURINE BRONCHODILATOR BRISTOL MAYERS KENKYUSHO KK 1982-10-07 JP disclosed
US-4241063-A Purine derivatives and their use as bronchodilators BRISTOL-MYERS COMPANY (US) 1980-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 YTHDC1 3048/4885TP53 2717/4885CYP2C9 1542/4885
US-20070190071-A1 9-Substituted 8-oxoadenine compound IFNAR1, IL5, IFNG YTHDC1 1035/4885TP53 4535/4885CYP2C9 976/4885
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates TLR3, TLR2, TLR1 YTHDC1 3411/4885TP53 1089/4885CYP2C9 1648/4885
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF PAICS, ENTPD5, PNP YTHDC1 772/4885TP53 946/4885CYP2C9 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.